QuidelOrtho Corp. Hits New 52-Week Low at $18.94 Amid Ongoing Struggles

QuidelOrtho Corp., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 18.94 as of March 10, 2026. This marks a significant decline, with the stock's performance over the past year showing a decrease of 53.06%, starkly contrasting with the S&P 500's gain of 20.78% during the same period. The company's market capitalization stands at USD 1,530 million, and it has faced ongoing financial difficulties, reporting negative results for the last 12 consecutive quarters. Key financial metrics reveal a debt-equity ratio of 1.31, indicating a higher reliance on debt, while the return on equity is at -7.95%. Additionally, the price-to-book ratio is 0.80, suggesting that the stock may be undervalued relative to its assets. QuidelOrtho's stock has consistently underperformed against the S&P 500 over the last three years, with a notable decline of 51.32% in the past year alone. The company's financial challenges and market position continue to be focal points for stakeholders as it navigates a difficult landscape.